Case reports: efalizumab-associated lymphoproliferative disease. J Drugs Dermatol 2007 Jun;6(6):646-8
Date
08/03/2007Pubmed ID
17668531Scopus ID
2-s2.0-34548462490 (requires institutional sign-in at Scopus site) 14 CitationsAbstract
Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.
Author List
Bommakanti S, Patil A, Eshoa C, Chitambar CRMESH terms used to index this publication - Major topics in bold
Antibodies, MonoclonalAntibodies, Monoclonal, Humanized
Herpesvirus 4, Human
Humans
Immunosuppressive Agents
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Lymphoproliferative Disorders
Male
Middle Aged
Psoriasis
